India Targeted for Inhaled Insulin Market

More than half-a-dozen pharmaceutical companies are boosting production to capture India, the biggest potential market for inhaled insulin in the world.

Eli Lilly has started clinical trials on Indian diabetes patients, while Pfizer announced that it has received the FDA and EC approval for commercial production of its inhaled insulin, Exubera. Pfizer plans to carry out clinical trials in India. Pfizer may launch Exubera in India in the next two years.

Physicians involved in Lilly’s trials claim that commercial production of inhaled insulin may begin next year. The study is being done in India by a contract research organization.

Source: Economic Times, February 7, 2006.